A Phase I Dose-Escalation Safety and Tolerability Study of Mirvetuximab Soravtansine (IMGN853) and Gemcitabine in Patients With FRa-positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial Cancer, or Triple Negative Breast Cancer (TNBC)

Trial Profile

A Phase I Dose-Escalation Safety and Tolerability Study of Mirvetuximab Soravtansine (IMGN853) and Gemcitabine in Patients With FRa-positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial Cancer, or Triple Negative Breast Cancer (TNBC)

Recruiting
Phase of Trial: Phase I

Latest Information Update: 19 Jul 2017

At a glance

  • Drugs Gemcitabine (Primary) ; Mirvetuximab soravtansine (Primary)
  • Indications Breast cancer; Endometrial cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer; Uterine cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 14 Apr 2017 Planned number of patients changed from 42 to 44.
    • 14 Apr 2017 Planned End Date changed from 1 Jun 2019 to 1 Mar 2019.
    • 14 Apr 2017 Planned primary completion date changed from 1 Jun 2019 to 1 Mar 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top